Hepatocellular carcinoma: research and therapeutic landscape

11 genes recurrently implicated in hepatocellular carcinoma, triaged for whether anything can actually be aimed at them. The zeros are the informative rows.

Of 11 recurrently implicated genes, 8 carry any drug at all. That is a statement about these 11 gene targets, not about the disease: Hepatocellular carcinoma does have labelled therapy — 12 drugs, listed in the next section.

Dataset evidence counts studies in the 307-study ranked set whose title or abstract names the gene; the bar is scaled to CTNNB1. Sources: Open Targets Platform and NCBI GEO, retrieved 2026-09-08. Clinical stage is the highest reached for any indication — see the per-drug indications noted in each row. Target-prioritisation reference only; not clinical or prescribing guidance.

12 drugs carry an FDA label naming hepatocellular carcinoma: Atezolizumab, Bevacizumab, Cabozantinib, Durvalumab, Ipilimumab, Lenvatinib, Nivolumab, Pembrolizumab, Ramucirumab, Regorafenib, Sorafenib, Tremelimumab. Separately, 29 of the drugs returned for the genes in the table above are approved only for other diseases and reach hepatocellular carcinoma through trials, not through their labels.

Every label that names hepatocellular carcinoma

24 labels match indications_and_usage:"hepatocellular carcinoma"; they collapse to 13 distinct molecules once salt forms, biosimilars and co-formulated hyaluronidase are merged. Diagnostic and contrast agents (Ethiodized Oil) are listed but are not treatments. Source: openFDA drug label API (api.fda.gov/drug/label.json), retrieved 2026-09-08. Labels change; this reflects the current label text, not the approval history. Not prescribing guidance.

GPC3 is the busiest cell-therapy antigen in hepatocellular carcinoma: 39 registered trials, 20 still active, 2 withdrawn before enrolling anyone.

10 of 39 shown, most recently active first. Other antigens searched: AFP (6), CD147 (3), MUC1 (3), EpCAM (1). Source: ClinicalTrials.gov API v2, retrieved 2026-09-08. Trials are matched on the antigen named in the title or intervention, so a trial stating only a product code is missed.

Every term below is a share of the hepatocellular carcinoma literature, not a count, because the field itself grew: 2015–2018 (n=6,000) against 2021–2025 (n=6,000). A topic whose papers doubled while the field doubled has not risen.

These are sample shares. The two windows hold 15,942 and 26,842 papers; MeSH terms were read from an evenly spaced sample of 6,000 and 6,000 of them, taken across the whole window rather than from its most recent papers. Percentages carry sampling error of roughly a percentage point and small differences between two terms are not meaningful.

Rising, with a real baseline

Cooling

Biggest topics now

Publication mix

Query: Carcinoma, Hepatocellular[MeSH Major Topic] NOT ("Cholangiocarcinoma"[MeSH] OR "Bile Duct Neoplasms"[MeSH] OR "Hepatoblastoma"[MeSH]). Terms need at least 12 papers in the recent window and, in the rising table, at least 5 in the earlier one — a term going from 1 paper to 12 is a large fold change and no evidence of anything. Ubiquitous descriptors (Humans, Animals, age bands) and the disease’s own term are dropped. Windows are read whole where they fit and sampled where they do not; the totals and the sample sizes are both in the JSON beside this page. Source: PubMed MeSH, retrieved 2026-09-08.

NIH obligations naming hepatocellular carcinoma, after removing the 241 records across all years that matched the search but are about something else. That filter is not cosmetic: without it this section reports another field’s funding as this disease’s.

NIH obligations by fiscal year

Where FY2025 money went

Text search hepatocellular carcinoma over project title, terms and abstract, per fiscal year. Awards are individual funding actions; distinct projects collapse them by core project number, so a multi-year grant counts once. The most recent year may be incomplete. Source: NIH RePORTER, retrieved 2026-09-08.

4,594 human GEO series match hepatocellular carcinoma. Keyword relevance cannot tell a 2,606-sample patient cohort from a six-well cell-line experiment, so this ranking scores four things GEO does not expose: how often the accession is named in full-text papers, field-normalised citation impact, clinical annotation, and cohort type.

Composition of the 307-study ranked set

Sources: NCBI GEO + Europe PMC + iCite, retrieved 2026-09-08. SubSeries are collapsed to one row per study by linked PMID. Of 723 series retrieved, 12 were dropped by the profile’s exclusion rules and 356 named the disease only in passing. The ranked set is a relevance-ranked sample, not a census, so the composition figures describe the sample only.

Each card below is a disagreement between two of the tables on this page — a drug that exists but was never tried here, a target that looks tested and was not, a gene with no drug whose product has a busy clinical programme. They are computed from the same facts as the tables, so they cannot contradict them.

This page is written to be quoted correctly by a model as much as read by a person. The same facts are available as JSON at the sibling URL below, which is what to cite.

{
  "disease": "Hepatocellular carcinoma",
  "mesh": "Carcinoma, Hepatocellular",
  "facts": "https://usebiotransfer.org/disease/hepatocellular-carcinoma.json",
  "methods": "https://usebiotransfer.org/methods/",
  "note": "Every figure on the page is in that JSON with its source and retrieval date. Quote from it rather than from the HTML."
}